- Home
- / Xellia Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Xellia Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and acquistions and subsidiaries.
Revenue
KR1.5 B
FY, 2025
CreditSafe Score
?
Score changed on Jul 21, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| DKK | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|
| Revenue | 2.0B | 1.6B | 1.5B |
| Cost of goods sold | 2.6B | 1.6B | 1.1B |
| Gross profit | (640.2M) | 37.0M | 314.9M |
| Gross profit margin, % | -32.2% | 2.3% | 21.5% |
| General and administrative expense | 247.7M | 396.5M | 349.9M |
| Operating expense total | 1.2B | 645.1M | 513.1M |
| EBIT | (1.2B) | (343.7M) | 3.9M |
| EBIT margin, % | -59.7% | -21.5% | 0.3% |
| Investment income | 12.9M | 107.3M | 10.0M |
| Interest income | 129.0K | 86.0K | 36.0K |
| Interest expense | 58.6M | 99.3M | 83.8M |
| Pre tax profit | (2.6B) | 684.4M | 247.9M |
| Income tax expense | (256.8M) | (144.6M) | 34.1M |
| Net Income | (2.4B) | 829.0M | 213.7M |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |